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Abstract
Background: Post-hepatectomy liver failure (PHLF) has been defined by the International Study Group
for Liver Surgery (ISGLS). The purpose of the present study was to examine the kinetics of conventional
liver function tests (LFT) after a major liver resection and is the first to examine their utility in predicting
PHLF in groups defined by the ISGLS.
Methods: Consecutive patients undergoing a major liver resection for colorectal liver metastases were
stratified into ISGLS groups and their LFT up to 1 year after surgery compared. Receiving-operating
characteristic (ROC) analysis of LFT identified optimal thresholds in predicting category C liver failure.
Results: In total, 32, 22 and 19 patients belonged to ISGLS groups A, B and C, respectively. The median
international normalized ratio (INR) and bilirubin values on post-operative days 1, 3, 5 and 7 were
significantly different among the groups (all P-values <0.05). ROC analysis of day 1 INR (AUC 0.813) and
day 5 bilirubin (AUC 0.798) revealed thresholds of 1.35 and 52 mmol/l to have sensitivities of 85% and
81% and specificities of 63% and 73%, respectively, to predict group C liver failure.
Discussion: Post-operative LFT after a major liver resection differs significantly among the three ISGLS
groups. Thresholds of bilirubin and INR can be used to identify patients who are at a maximum risk of
complications.
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Introduction
Post-hepatectomy liver failure (PHLF) remains an important
cause of morbidity and mortality after a major liver resection1–4
which is performed increasingly for curative resection of colorec-
tal liver metastases (CRLM) in the western world.5–8 Monitoring
liver function after surgery is essential to prevent, recognize, prog-
nosticate and manage PHLF. While there are many excellent
quantitative9–12 and volumetric studies13 that address this issue,
conventional biochemical liver function tests (LFT) evaluated by
routine blood test analysis remain widely used and form an indis-
pensible part of most definitions of liver failure.14–16 The Interna-
tional Study Group for Liver Surgery (ISGLS) has recently
proposed a definition for liver failure, grading patients into three
groups based on the clinical severity of their post-operative hos-
pital course.17 There are a few contemporary studies that have
evaluated the long-term kinetics of post-operative biochemical
LFT after a major liver resection18,19 and none to the authors
knowledge in groups stratified as per the ISGLS definition. Most
studies also include major as well as minor resection for primary
hepatobiliary malignancies, metastases and benign conditions.
Earlier studies20,21 do not provide a comparison of LFT in patients
with and without surgery-related morbidity and may not be rep-
resentative of the current population. Finally, background liver
function and pre-existing liver disease will affect the post-
operative course of LFT and likelihood of PHLF. Thresholds of
LFT to predict PHLF using a common definition will vary
between patients with different pathology. The objectives of this
study were therefore twofold: (i) to examine the kinetics of
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conventional LFT for 1 year in patients who underwent a major
liver resection for CRLM stratified into three groups as per the
ISGLS guidelines for post-hepatectomy liver failure and (ii) to
identify the utility of LFT in predicting category C PHLF in
patients undergoing resection solely for CRLM.
Methodology
Patients
This study is a retrospective analysis of a prospective liver surgery
database maintained at St James’s University Hospital, Leeds, UK.
Consecutive patients who underwent a major liver resection
(defined as resection of three or more Couinaud’s segments) by a
single surgeon (J.P.A.L.) for CRLM from January 2005 to Decem-
ber 2010 were identified (n = 77). Patients who underwent resec-
tion for other diagnoses, e.g. hepatocellular carcinoma and
cholangiocarcinoma were excluded. Patients who developed post-
operative jaundice as a result of causes other than parenchymal
insufficiency (e.g. drug induced/mechanical biliary obstruction)
or whose notes were incomplete were excluded (n = 4). Patient
management was discussed at a multidisciplinary team meeting to
plan optimal pre-operative treatment, a resection strategy and
post-operative care pathways.
Case records were reviewed to examine the clinical course of
patients to classify them into the three groups as per the ISGLS
proposal.17 Briefly, patients were classified into Group A if they
had a normal clinical course or an inconsequential transient eleva-
tion of LFT. Group B patients included those who required a
change in their clinical management, e.g. a longer stay in the
high-dependency unit, the use of diuretics for ascites, non-
invasive ventilation etc. Group C patients needed invasive man-
agement, e.g. the use of inotropes/invasive ventilation and
percutaneous catheter drainage of ascites/pleural effusion. The
electronic results server was searched to retrieve the values of
bilirubin, alanine aminotransferase (ALT), alkaline phosphatase
(ALP), albumin, international normalized ratio (INR), platelet
count and C-reactive protein (CRP) pre-operatively, on the day of
surgery and on post-operative days 1, 3, 5, 7 and 10. Also all these
values (except CRP) were obtained routinely as per follow-up
protocols at 3, 6 months and 1 year after surgery. The hospital
reference range for liver function tests are as follows: bilirubin
1.7–17 mmoL/l, ALT 9–40 U/l, ALP 44–147 IU/l, albumin
35–50 g/l, INR 0.8–1.2, platelet count 150–400 000/ml and CRP
5–119 mg/l.
Data analysis
The median values of each investigation were plotted for each
group at the above-mentioned time points to obtain graphs dis-
playing their comparative kinetics. The course of LFT in the three
ISGLS groups in the first post-operative week was compared. Sta-
tistical analysis was performed using SPSS 17.0 (SPSS, Inc.,
Chicago, IL, USA). Categorical variables that might influence LFT
or hospital course were compared among the three ISGLS groups
using Pearson’s chi-squared test. Age > 70 years, gender, the pres-
ence of co-morbidities (diabetes, hypertension and coronary
artery disease), the use of Pringle’s manoeuvre, the use of adjuvant
chemotherapy (for primary colorectal cancer) prior to surgery, a
pre-operative neutrophil–lymphocyte ratio and liver histology of
the resected specimen (steatosis/fibrosis/sinusoidal obstructive
syndrome) were the variables compared. Continuous variables
were expressed as the median, range. LFT on post-operative days
1, 3, 5 and 7 were compared among the three ISGLF groups using
the Kruskal–Wallis test. Receiver-operating characteristic (ROC)
curves were plotted to identify optimal thresholds for LFT vari-
ables found to be significantly different between ISGLS groups.
The area under the curve (AUC), sensitivity and specificity of
various thresholds were computed. A P-value of less than 0.05 was
considered significant.
Results
A total of 73 patients satisfied the selection criteria for this study.
There were 47 males and 26 females. Thirty-two patients had an
uncomplicated hospital course with only transient elevation of
bilirubin and INR and belonged to group A. There were 22 and 19
patients in groups B and C, respectively. Table 1 gives a compari-
son of variables that might influence LFT and hospital course
among the three groups. The rate of complications was the only
parameter that was significantly different among the three groups
(P = 0.011).
A comparison of LFT, platelet count and CRP in the first week
after surgery is given in Table 2. Only bilirubin and INR levels
were repeatedly and significantly different between the three
groups within the first week after a liver resection. The trends of
bilirubin and INR levels after resection are depicted in Fig. 1a–b.
The median bilirubin of group A remained mostly less than
20 mmol/l during the first week after surgery and this trend con-
tinued to 1 year of follow-up. Patients in group B had a bilirubin
of 46 mmol/l on day 5 and a peak of 69 mmol/l on day 10 after
which the levels dropped to the normal range at the first follow-up
at 3 months. Group C patients had a steady climb of bilirubin with
values of 92 mmol/l on day 5, a peak of 112 mmol/l on day 10 and
a steep decline after 2 weeks to normal levels at 3 months (Fig. 1a).
The median INR values peaked at 1.4 on day 3, 1.8 on day 3, 1.8
on day 1 for groups A, B and C, respectively. After day 5, the INR
decreased steadily in all groups with values at 1, 1.2 and 1.3 on day
10 in groups A, B and C, respectively. Group C patients had
normal values at the second follow-up at 6 months after surgery
(Fig. 1b). There was no significant or sustained difference in the
kinetics of other parameters measured between the three groups
(data not presented).
A comparison of ROC curves for INR and bilirubin at post-
operative days 1, 3, 5 and 7 is given in Table 3. The optimum times
to identify patients with group C liver failure utilized INR values
at post-operative day 1 and bilirubin values at day 5 (Fig. 2). An
INR of 1.35 on day 1 had a sensitivity and specificity of 85% and
63%, respectively, in predicting group C liver failure. A bilirubin of
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Table 1 Comparison of variables by International Study Group for Liver Surgery groups after a major liver resection for colorectal liver
metastases
Variable Group A Group B Group C P-valuea
Number of patients, n 32 22 19
Age>70 years, n (%) 7 (21.9) 9 (40.9) 6 (31.6) 0.322
Gender (M : F) 22:10 13:9 12:7 0.761
Comorbidityb, n (%) 12 (37.5) 11 (50) 6 (31.6) 0.458
Resection of 4 or more segments 18 (56.3) 12 (54.5) 13 (68.4) 0.614
Resection of 5 or more segments 9 (28.1) 6 (27.3) 4 (21.1) 0.603
Synchronous colonic resection 0 (0) 2 (9.1) 1 (5.3) 0.264
Pringle manoeuvre, n (%) 20 (62.5) 13 (59.1) 15 (78.9) 0.521
Intra-operative transfusion 1 (3.1) 1 (4.5) 1 (5.3) 0.935
Complications, n (%) 3 (9.4) 7 (31.8) 8 (42.1) 0.011
Adjuvant chemotherapy for primary tumour, n (%) 16 (50) 9 (40.1) 6 (31.6) 0.186
Pre-operative NLR > 5, n (%) 6 (18.6) 5 (22.6) 5 (26.3) 0.837
Liver histologyc, n (%) 22 (68.8) 12 (54.5) 10 (52.6) 0.535
NLR, neutrophil to lymphocyte ratio.
aPearson's chi-squared test.
bDiabetes, hypertension or coronary artery disease.
cSteatosis, fibrosis or sinusoidal obstructive syndrome.
Table 2 Comparison of biochemical parameters in the first week in the three (International Study Group for Liver Surgery) groups after a
major liver resection for colorectal liver metastases
Post-operative parameter ISGLS group Day 1 Day 3 Day 5 Day 7
Bilirubin
mmol/l
A 23.5 (8–60) 24.5 (12–75) 22.0 (7–93) 17.0 (7–123)
B 30.0 (13–140) 42.5 (13–82) 43.0 (12–115) 38.5 (15–156)
C 43.5 (13–104) 56.0 (8–126) 68.0 (10–206) 109.0 (13–335)
P = 0.007 0.001 0.004 0.001
Alanine amino-transferase
U/l
A 185.0 (48–435) 121.0 (29–284) 86.0 (44–154) 70.0 (25–173)
B 238.5 (114–904) 128.0 (47–516) 93.5 (31–226) 86.0 (26–155)
C 225.0 (37–1344) 113.0 (69–1122) 98.0 (52–610) 83.0 (49–301)
P = 0.115 0.587 0.508 0.175
Alkaline phosphatase
IU/l
A 198.5 (84–386) 208.5 (100–2472) 389.5 (186–776) 454.0 (240–1137)
B 209.5 (90–748) 222.0 (104–663) 358.0 (106–985) 833.0 (224–1870)
C 163.0 (106–693) 198.0 (104–499) 358.0 (115–874) 631.0 (225–2740)
P = 0.646 0.879 0.542 0.326
Albumin
g/l
A 29.5 (24–43) 35.0 (29–44) 36.0 (31–48) 36.0 (32–44)
B 30.0 (20–43) 32.0 (28–41) 34.0 (25–42) 33.5 (27–38)
C 29.5 (26–36) 36.0 (22–39) 34.5 (26–45) 34.0 (27–40)
P = 0.899 0.041 0.025 0.129
International normalized ratio A 1.4 (1.0–1.8) 1.4 (1.0–2.2) 1.2 (1.0–1.5) 1.1 (1.0–1.2)
B 1.5 (1.0–2.2) 1.8 (1.2–3.0) 1.4 (1.0–2.4) 1.2 (0.9–2.0)
C 1.8 (1.6–2.6) 1.7 (1.4–2.8) 1.6 (1.2–1.9) 1.4 (1.0–1.6)
P = 0.000 0.017 0.001 0.031
Platelet count
¥1000/ml
A 219.0 (107–325) 167.5 (95–227) 224.0 (142–362) 294.5 (186–473)
B 191.0 (112–354) 171.5 (100–333) 204.0 (140–454) 285.0 (155–551)
C 189.0 (72–349) 155.0 (57–272) 193.0 (93–332) 202.5 (103–470)
P = 0.437 0.865 0.556 0.050
C-reactive protein
mg/l
A 29.0 (12–115) 86.0 (19–194) 51.0 (29–138) 37.0 (20–44)
B 29.0 (14–204) 69.0 (22–158) 55.0 (17–240) 70.0 (24–196)
C 31.0 (11–96) 57.0 (28–159) 49.0 (6–224) 63.0 (9–245)
P = 0.950 0.217 0.948 0.079
ISGLS, International Study Group for Liver Surgery. Values in cells represent median (range) and P-value by Kruskal–Wallis test.
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52 on day 5 had a sensitivity and specificity of 81% and 73%,
respectively, in predicting group C liver failure.
Discussion
This study was designed to evaluate post-operative LFT in groups
stratified according to the ISGLS definition and assess their utility
in predicting category C liver failure. Although it is a retrospective
series with small numbers, there is a statistically significant differ-
ence in the kinetics of LFT in the three groups in the first post-
operative week and this trend persists when followed over a period
of 1 year. Previous studies have examined the course of LFT in
patients undergoing a liver resection. These have included patients
undergoing a major as well as minor resection and included
patients with all diagnoses.20,21 In the majority of studies, the
duration of follow-up has been for a short period of time. In a
recent study19, the post-operative changes in LFT in a cohort of
835 patients undergoing liver resection identified that the serum
bilirubin and INR differed based on the extent of resection. Fur-
thermore, these were significantly affected by complications
irrespective of the extent of resection. This study included 172
patients who underwent major liver resection for CRLM;
however, detailed analysis of this subgroup was not provided. It
was concluded that biochemical data may help recognize surgery-
related complications early during the post-operative course and
serve as the basis for the definition of complications after a hepatic
resection. In the current series, a homogenous group of patients
who underwent a major liver resection for CRLM were included.
The number of patients who underwent a resection of four or five
segments was not different among the three groups. The degree of
hepatic steatosis, cirrhosis or sinusoidal obstruction syndrome
was not different in the biopsy specimens among the three groups
(Table 1). The patients in this study group had ‘normal livers’
pre-operatively. Patients undergoing a resection for non-CRLM
(such as hilar cholangiocarcinoma or hepatocellular carcinoma)
were excluded to avoid confounding factors related to pre-
operatively deranged LFT and background liver dysfunction. The
senior author follows a policy of upfront surgery when the metas-
tases are resectable. So chemotherapy induced hepatotoxicity was
not a problem. It was not possible to control for administration of
adjuvant chemotherapy for the primary tumour but the propor-
tion receiving this was not significantly different among the three
ISGLS groups. Although volumetry and portal vein embolization
were not used, this factor could not have differentially impacted
the post-operative LFT in the three groups as the extent of resec-
tion was not different. Operative factors such as use the Pringle’s
manoeuvre, blood loss, etc. were not different among the three
groups. All procedures were performed by the senior author
(J.P.A.L.) and this also reduced variation as a result of surgeon
expertise. Thus, the present study analysed LFT in patients strati-
fied not according to the extent of resection or underlying disease
severity but according to the severity of their post-operative clini-
cal course as reflected by ISGLS categorization.
Bilirubin and INR have been well documented to predict PHLF
and outcome after a liver resection.13–15,22 What is novel is the fact
that, to the authors’ knowledge, this is the first study that docu-
ments that bilirubin and INR in the first week after a major liver
resection are significantly different in the three categories of liver
failure as defined by the ISGLS. This difference in kinetics of LFT
persists well into the post-operative course. It is noteworthy that
bilirubin levels in group B and C patients continued to be elevated
in the second week and took up to 3 months to return to normal
levels. This implies that it would be useful to mark out patients
who are likely to have category C liver failure in the first week and
direct resources towards them. The courses of ALT, ALP, platelets
and albumin have less clinical importance in this context. CRP
levels were not significantly different in the three groups in this
study. Post-operative CRP levels on days 1 and 3 have been dem-
onstrated to be significantly lower in patients with extended resec-
tions and in those with PHLF.23 CRP seems to be of value in early
differentiation of those with and without liver failure but of
limited value in further stratification of these patients into ISGLS
















































Figure 1 Post-operative kinetics of bilirubin (a) and the international
normalized ratio (INR) (b) after a major liver resection for colorectal
liver metastases. The median values are plotted over time for
patients grouped as per the International Study Group for Liver
Surgery
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liver in addition to the regenerative process and also varies with
the presence of complications.
This study has followed LFT for 1 year after surgery. It is note-
worthy that bilirubin levels in group B and C patients continued
to be elevated in the second week and took up to 3 months to
return to normal levels. The presented study group included
patients undergoing an extensive resection (five or more Couin-
aud’s segments). The proportion of patients undergoing an exten-
sive resection was not different between the ISGLS groups
although the only two post-operative deaths occurred in patients
with an extensive resection and within ISGLS group C.
The utility of bilirubin and INR in predicting PHLF is exam-
ined by this study. ROC curves identified that post-operative day
1 INR and day 5 bilirubin values presented the highest sensitivity
and specificity in predicting group C liver failure. The bilirubin
value of 52 mmol/l at post-operative day 5 identified in the present
study matches that of Balzan et al..14 In that study the conjunction
of prothrombin time of <50% and bilirubin > 50 mmol/l on post-
operative day 5 was a strong predictive factor of mortality which
have since become popular as the ‘50-50’ criteria and have been
prospectively validated.24 Mullen et al.16 in a study of major liver
resection in 1059 patients with non-cirrhotic livers showed by
ROC analysis that a post-operative bilirubin of more than 7 mg/dl
and INR of more than 2 were predictors of 90-day mortality.
When these higher cut-off values were applied to the presented
study population, it resulted in high specificities but low sensitivi-
ties for detection of group C liver failure. While the aforemen-
tioned studies used different thresholds of bilirubin and INR to
define PHLF and predict mortality, the present study has used the
ISGLS definition for liver failure and attempted to identify thresh-
olds that identify the most critical subset of patients with liver
failure (group C).
Whether the low specificity of thresholds of INR and bilirubin
in this study on post-operative days 1 and 5 affect clinical utility,
is a point that merits discussion. The conclusions of this paper are
not practice changing and as has been the case with previous
studies, biochemical tests alone cannot infallibly predict post-
operative liver failure. Nevertheless, the data presented details the
sensitivity and specificity of these two simple laboratory markers
and thus their clinical utility in predicting ISGLS category C liver
failure can be quantified. Day 1 INR > 1.35 would identify 85% of
the people with category C PHLF, whereas day 5 bilirubin would
do the same in 81% of the patients. Whereas, with the same
thresholds for INR and bilirubin only 63% and 73% of patients
without category C PHLF would be correctly identified as not
having this condition. Thus, the false-positive rate (number of
‘normal people’ diagnosed to have PHLF) is high. An INR of >
1.35 on day 1 would falsely categorize 37% of the patients as at risk
Table 3 Comparison of receiver-operating curve (ROC) characteristics for the international normalized ration (INR) and bilirubin at post-
operative days 1, 3, 5 and 7 to predict category C liver failure. The largest AUC for INR and bilirubin levels were observed on post operative
days 1 and 5, respectively (in bold)
Post-operative day AUC Standard error P-value 95% CI of AUC
Bilirubin 1 0.678 0.086 0.049 0.510 to 0.847
3 0.744 0.087 0.007 0.574 to 0.914
5 0.798 0.076 0.001 0.649 to 0.946
7 0.739 0.105 0.040 0.534 to 0.945
INR 1 0.813 0.065 0.001 0.685 to 0.941
3 0.705 0.091 0.042 0.527 to 0.883
5 0.744 0.016 0.016 0.586 to 0.901
7 0.718 0.106 0.062 0.511 to 0.926


















Figure 2 Receiver-operating characteristics (ROC) curves for post-
operative day 1 international normalized ration (INR) and day 5
bilirubin demonstrating their utility in predicting Group C post-
operative liver failure (as per the International Study Group for Liver
Surgery) in patients undergoing a major liver resection for colorectal
liver metastases
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for category C PHLF; a day 5 bilirubin > 52 would have a false
positivity of 27%. This does not negate their clinical utility as over
diagnosing a serious problem (low specificity) is less of a problem
than missing it (low sensitivity). The issue of low specificity and
heterogeneity is also inherent in the ISGLS definition of PHLF. It
is an inclusive definition designed to identify serious problems
that affect the patient’s hospital course and outcome. For instance,
a patient with a minor bile leak from the transection surface can
require image-guided percutaneous catheter placement. This may
be a minor inconvenience clinically; however, it does place the
patient in category C. In the present study, this definition has been
utilized as it provides a standardized platform for reporting and
comparison of outcomes and shown that it definitely stratifies
patients into true groups as far the LFT are concerned.
If the study had incorporated greater numbers of patients mul-
tivariate analysis would have been feasible and possibly strength-
ened the results. However, even with the numbers of subjects in
this study, the paper has clearly demonstrated what it set out to
prove – the post-operative kinetics of LFT in patients undergoing
major liver function are different in patients stratified into the
three ISGLS groups. While no method is perfect in predicting
patients who would develop PHLF, simple LFT are indispensible
and this paper adds perspective to their clinical utility.
To conclude, this study examines the long-term post-operative
kinetics of LFT and their utility in predicting PHLF in patients
undergoing a liver resection. Its strengths are the inclusion of only
patients who underwent a major liver resection (who are most
vulnerable to develop this complication) for CRLM (the most
common indication for liver resection in the western population).
This study has also used a standard definition of PHLF recently
proposed by the ISGLS and quantified the utility of simple labo-
ratory tests (day 1 INR and day 5 bilirubin) in predicting patients
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